title: The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?
authors.forename: Susanna B
authors.initials: SB
authors.lastname: Park
authors.forename: Cindy S-Y
authors.initials: CS
authors.lastname: Lin
authors.forename: Arun V
authors.initials: AV
authors.lastname: Krishnan
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Kiernan
mesh_terms: D020816:Amino Acid Motifs; D000970:Antineoplastic Agents / Q000009:adverse effects*; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011110:Polymorphism, Genetic; D051640:Small-Conductance Calcium-Activated Potassium Channels / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; C406328:KCNN3 protein, human; D009944:Organoplatinum Compounds; D051640:Small-Conductance Calcium-Activated Potassium Channels; D000077150:Oxaliplatin